title: High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
authors.affiliation: Department of Urology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors.forename: Jason B
authors.initials: JB
authors.lastname: Muhitch
authors.forename: Thomas
authors.initials: T
authors.lastname: Schwaab
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology / Q000556:secondary*; D016207:Cytokines / Q000097:blood; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000097:blood / Q000276:immunology; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D016207:Cytokines; D007376:Interleukin-2
keywords: immunotherapy; interleukin-2; kidney cancer; metastatic renal cell carcinoma